Quinazoline derivatives as tyrosine kinase inhibitors

Details for Australian Patent Application No. 2004272348 (hide)

Owner AstraZeneca AB

Inventors Hennequin, Laurent Francois Andre; Halsall, Christopher Thomas

Agent Davies Collison Cave

Pub. Number AU-B-2004272348

PCT Pub. Number WO2005/026150

Priority 0406163.6 19.03.04 GB; 0321620.7 16.09.03 GB

Filing date 13 September 2004

Wipo publication date 24 March 2005

Acceptance publication date 4 September 2008

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 405/14 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

30 March 2006 PCT application entered the National Phase

  PCT publication WO2005/026150 Priority application(s): WO2005/026150

4 September 2008 Application Accepted

  Published as AU-B-2004272348

8 January 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004272350-Quinazoline derivatives as tyrosine kinase inhibitors

2004272347-Water soluble package and process for producing it